Long-Term Efficacy of Vismodegib After its Withdrawal and Patients ’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)

ConclusionThe results of this exploratory analysis of vismodegib withdrawal are consistent with a substantial link between treatment response and patients ’ HRQoL. Furthermore, 11 out of 35 (31%) patients that reported a complete remission of the disease after 6 months of vismodegib treatment reported BCC recurrence. These data highlight the importance of continuous follow-up and perhaps different regimens of treatment, such as an alternate dose re gimen to maintain disease control and reduce the adverse events as previously described in the literature.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research